Block Listing Interim Review

Aptamer Group PLC

29 February 2024

 

29 February 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Listing Interim Review

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	25 August 2023 to 24 February 2024
Number and class of securities not issued at the start of the period under the scheme	1,666,477 Ordinary Shares
Number of securities issued under the scheme during the period	0
Balance under the scheme of securities not yet issued at the end of the period	1,666,477 Ordinary Shares
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Andrew Rapson [phone]

- ENDS -

For further information, please contact:

Aptamer Group plc Steve Hull	[phone]
SPARK Advisory Partners Limited - Nominated Adviser   Andrew Emmott / Mark Brady / Adam Dawes	[phone]
Turner Pope Investments (TPI) Limited - Broker   James Pope / Andrew Thacker	[phone]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

 

END